Titre :
  • Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.
Auteur : Awada, Ahmad ; Hendlisz, Alain ; Gil, Thierry ; Bartholomeus, Sylvie ; Mano, Max S. ; De Valeriola, Dominique ; Strumberg, Dirk ; Brendel, Erich ; Haase, Claus G ; Schwartz, Brian ; Piccart-Gebhart, Martine
Informations sur la publication : British Journal of Cancer, 92, 10, (page 1855-1861)
Statut de publication : Publié, 2005-05
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés : BAY 43-9006
Efficacy
Pharmacokinetics
Safety
Solid tumours
Targeted agent
Mots-clés MeSH : Adult
Aged
Benzenesulfonates -- administration & dosage
Benzenesulfonates -- adverse effects
Benzenesulfonates -- pharmacokinetics
Carcinoma, Renal Cell -- drug therapy
Drug Administration Schedule
Female
Humans
Kidney Neoplasms -- drug therapy
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms -- drug therapy
Pyridines -- administration & dosage
Pyridines -- adverse effects
Pyridines -- pharmacokinetics
Note : Clinical Trial
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langue :
  • Anglais
Identificateurs : urn:issn:0007-0920 
info:doi/10.1038/sj.bjc.6602584
info:pii/6602584
info:pmid/15870716
info:pmcid/PMC2361774